{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:53:29Z","timestamp":1793710409914,"version":"4.6.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T00:00:00Z","timestamp":1677974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T00:00:00Z","timestamp":1677974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Miltenyi"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00432-023-04660-y","type":"journal-article","created":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T03:02:31Z","timestamp":1677985351000},"page":"7091-7101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma: real-world evidence from a German claims database"],"prefix":"10.1007","volume":"149","author":[{"given":"Peter","family":"Borchmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Michel","family":"Heger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1110-2793","authenticated-orcid":false,"given":"J\u00f6rg","family":"Mahlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Papadimitrious","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybille","family":"Riou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,5]]},"reference":[{"key":"4660_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00432-015-2017-z","volume":"142","author":"K Adzersen","year":"2016","unstructured":"Adzersen K, Friedrich S, Becker N (2016) Are epidemiological data on lymphoma incidence comparable? Results from an application of the coding recommendations of WHO, InterLymph, ENCR and SEER to a cancer registry dataset. J Cancer Res Clin Oncol 142:167\u2013175","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9383","key":"4660_CR2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","volume":"362","author":"KM Ardeshna","year":"2003","unstructured":"Ardeshna KM, Smith P, Norton A et al (2003) British national lymphoma investigation. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362(9383):516\u2013522","journal-title":"Lancet"},{"issue":"1","key":"4660_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2007-01-041871","volume":"110","author":"J Armitage","year":"2007","unstructured":"Armitage J (2007) How I treat patients with diffuse large B-cell lymphoma. Blood 110(1):29\u201336","journal-title":"Blood"},{"issue":"6","key":"4660_CR4","first-page":"1","volume":"22","author":"M Bl\u00fcmel","year":"2020","unstructured":"Bl\u00fcmel M, Spranger A, Achstetter K et al (2020) Germany: health system review. Health Syst Transit 22(6):1\u2013273","journal-title":"Health Syst Transit"},{"issue":"11\u201312","key":"4660_CR5","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1159\/000509973","volume":"104","author":"M B\u00f6gemann","year":"2020","unstructured":"B\u00f6gemann M, Zagorska A, Akumo D et al (2020) Using data from a sickness fund claims database to assess the treatment patterns and healthcare resource utilization among patients with metastatic renal cell carcinoma in Germany. Urol Int 104(11\u201312):982\u2013993","journal-title":"Urol Int"},{"key":"4660_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40487-022-00211-6","volume":"11","author":"P Borchmann","year":"2023","unstructured":"Borchmann P, Heger J-M, Mahlich J et al (2023) Healthcare resource utilization and associated costs of German patients with diffuse large B-cell lymphoma\u2014a retrospective health claims data analysis. Oncol Ther 11:65\u201381. https:\/\/doi.org\/10.1007\/s40487-022-00211-6","journal-title":"Oncol Ther"},{"issue":"16","key":"4660_CR7","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800\u20131808","journal-title":"Blood"},{"key":"4660_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.zefq.2016.10.004","volume":"118","author":"J Czwikla","year":"2016","unstructured":"Czwikla J, Domhoff D, Giersiepen K (2016) ICD coding quality for outpatient cancer diagnoses in SHI claims data. Z Evid Fortbild Qual Gesundh Wesen 118:48\u201355","journal-title":"Z Evid Fortbild Qual Gesundh Wesen"},{"key":"4660_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.824704","volume":"12","author":"W Daneels","year":"2022","unstructured":"Daneels W, Rosskamp M, Macq G et al (2022) Real-world estimation of first- and second-line treatments for diffuse large B-cell lymphoma using health insurance data: a Belgian population-based study. Front Oncol 12:824704","journal-title":"Front Oncol"},{"issue":"3","key":"4660_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41408-022-00637-1","volume":"12","author":"M Durmaz","year":"2022","unstructured":"Durmaz M, Visser O, Posthuma E et al (2022) Time trends in primary therapy and relative survival of diffuse large B cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989\u20132018. Blood Cancer J 12(3):38","journal-title":"Blood Cancer J"},{"key":"4660_CR11","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1038\/s41416-022-01931-2","volume":"127","author":"D Ekberg","year":"2022","unstructured":"Ekberg D, Crowther M et al (2022) Patient trajectories after diagnosis of diffuse large B-cell lymphoma\u2014a multistate modelling approach to estimate the chance of lasting remission. Br J Cancer 127:1642\u20131649","journal-title":"Br J Cancer"},{"key":"4660_CR12","doi-asserted-by":"publisher","first-page":"5519","DOI":"10.1002\/cam4.3237","volume":"9","author":"N Epperla","year":"2020","unstructured":"Epperla N, Vaughn J, Othus M et al (2020) Recent survival trends in diffuse large B-cell lymphoma\u2013\u2013have we made any progress beyond rituximab? Cancer Med 9:5519\u20135525","journal-title":"Cancer Med"},{"issue":"28","key":"4660_CR13","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.1200\/JCO.2007.15.9277","volume":"26","author":"K Fu","year":"2008","unstructured":"Fu K, Weisenburger D, Choi W et al (2008) Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B cell-like and non-germinal center B cell-like subtypes of diffuse large B cell lymphoma. J Clin Oncol 26(28):4587\u20134594","journal-title":"J Clin Oncol"},{"key":"4660_CR14","unstructured":"GBA [Gemeinsamer Bundesauschuss] (2020) Nutzenbewertungsverfahren zum Wirkstoff Polatuzumab Vedotin. Available: https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/518\/#dossier. Accessed 30 Aug 2022"},{"key":"4660_CR15","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/bjh.15412","volume":"182","author":"C Gisselbrecht","year":"2018","unstructured":"Gisselbrecht C, Van Den Neste E (2018) How I manage patients with relapsed\/refractory diffuse large B cell lymphoma. Br J Haematol 182:633\u2013643","journal-title":"Br J Haematol"},{"key":"4660_CR16","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/cncr.25247","volume":"116","author":"E Jabbour","year":"2010","unstructured":"Jabbour E, Thomas D, Cortes J, Kantarjian HM, O\u2019Brien S (2010) Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer 116:2290\u20132300","journal-title":"Cancer"},{"issue":"1","key":"4660_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","volume":"63","author":"G Kanas","year":"2022","unstructured":"Kanas G, Ge W, Quek R et al (2022) Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020\u20132025. Leuk Lymphoma 63(1):54\u201363","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"4660_CR18","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1200\/JCO.2009.24.5860","volume":"28","author":"JF Larouche","year":"2010","unstructured":"Larouche JF, Berger F et al (2010) Lymphoma recurrence 5 years or later following diffuse large B-Cell lymphoma: clinical characteristics and outcome. J Clin Oncol 28(12):2094\u20132100","journal-title":"J Clin Oncol"},{"issue":"7","key":"4660_CR19","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1007\/s12325-019-00969-8","volume":"36","author":"J Mahlich","year":"2019","unstructured":"Mahlich J, Alba A, El Hadad L et al (2019) Drug survival of biological therapies for psoriasis treatment in Germany and associated costs: a retrospective claims database analysis. Adv Ther 36(7):1684\u20131699","journal-title":"Adv Ther"},{"issue":"1","key":"4660_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40261-020-00990-8","volume":"41","author":"J Mahlich","year":"2021","unstructured":"Mahlich J, Olbrich K, Wilk A et al (2021) Time to treatment discontinuation in German patients with Schizophrenia: Long acting injectables versus oral antipsychotics. Clin Drug Investig 41(1):99\u2013113","journal-title":"Clin Drug Investig"},{"issue":"7","key":"4660_CR21","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.clml.2021.12.018","volume":"22","author":"B Moertl","year":"2022","unstructured":"Moertl B, Dreyling M, Schmidt C et al (2022) Inpatient treatment of relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL): a health economic perspective. Clin Lymphoma Myeloma Leuk 22(7):474\u2013482","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4660_CR22","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.2217\/fon-2018-0267","volume":"14","author":"VA Morrison","year":"2018","unstructured":"Morrison VA, Bell JA, Hamilton L et al (2018) Economic burden of patients with diffuse large B cell and follicular lymphoma treated in the USA. Future Oncol 14:2627\u20132642","journal-title":"Future Oncol"},{"key":"4660_CR23","unstructured":"NIH [National Institutes of Health] (2022) Surveillance, Epidemiology, and End Results (SEER). Cancer Stat Facts: NHL - Diffuse Large B-Cell Lymphoma (DLBCL). Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html. Accessed 20 Oct 2022"},{"key":"4660_CR24","doi-asserted-by":"publisher","DOI":"10.1200\/GO.21.00265","volume":"8","author":"M Pavlovsky","year":"2022","unstructured":"Pavlovsky M, Cubero D, Agreda-Vasquez G et al (2022) Clinical outcomes of patients with B cell non-Hodgkin lymphoma in real-world settings: findings from the hemato-oncology Latin America observational registry study. JCO Global Oncology 8:e2100265","journal-title":"JCO Global Oncology"},{"issue":"5","key":"4660_CR25","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3109\/10428194.2012.734616","volume":"54","author":"D Pulte","year":"2013","unstructured":"Pulte D, Jansen L, Gondos A et al (2013) Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century. Leuk Lymphoma 54(5):979\u2013985","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"4660_CR26","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1634\/theoncologist.2018-0490","volume":"24","author":"A Purdum","year":"2019","unstructured":"Purdum A, Tieu R, Reddy S, Broder M (2019) Direct costs associated with relapsed diffuse large B cell lymphoma therapies. Oncologist 24(9):1229\u20131236","journal-title":"Oncologist"},{"key":"4660_CR27","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40801-022-00320-8","volume":"9","author":"C Scheid","year":"2022","unstructured":"Scheid C, Kudernatsch R, Eckart M et al (2022) Treatment pathways and health outcomes of German patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation: a retrospective health claims data analysis. Drugs Real World Outcomes 9:577\u2013588","journal-title":"Drugs Real World Outcomes"},{"key":"4660_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s10389-022-01736-w","author":"C Scheid","year":"2023","unstructured":"Scheid C, Kudernatsch R, Eckart M et al (2023) Incidence of graft-versus-host-disease in Germany: evidence from health care claims data. J Public Health. https:\/\/doi.org\/10.1007\/s10389-022-01736-w","journal-title":"J Public Health"},{"issue":"13","key":"4660_CR29","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1080\/10428194.2019.1623886","volume":"60","author":"J Shaw","year":"2019","unstructured":"Shaw J, Harvey C, Richards C et al (2019) Temporal trends in treatment and survival of older adult diffuse large B cell lymphoma patients in the SEER-Medicare linked database. Leuk Lymphoma 60(13):3235\u20133243","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"4660_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237509","volume":"15","author":"S Tsutsu\u00e9","year":"2020","unstructured":"Tsutsu\u00e9 S, Tobinai K, Yi J et al (2020) Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B cell lymphoma. PLoS ONE 15(8):e0237509","journal-title":"PLoS ONE"},{"issue":"6","key":"4660_CR31","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1055\/a-1493-4817","volume":"26","author":"C Wolff-Menzler","year":"2021","unstructured":"Wolff-Menzler C, Mahlich J, Olbrich K et al (2021) Hospitalisierungen und Behandlungskosten von Schizophreniepatienten nach Umstellung auf Depot-Antispsychotika. Gesundheits\u00f6konomie und Qualit\u00e4tsmanagement 26(6):302\u2013309","journal-title":"Gesundheits\u00f6konomie und Qualit\u00e4tsmanagement"},{"key":"4660_CR32","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1007\/s00432-020-03279-7","volume":"146","author":"M Yamamoto","year":"2020","unstructured":"Yamamoto M, Suzuki I, Saitou K et al (2020) Impact of comorbidity and relative dose intensity on outcomes in diffuse large B cell lymphoma patients treated with R-CHOP. J Cancer Res Clin Oncol 146:2995\u20133002","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"4660_CR33","doi-asserted-by":"publisher","first-page":"e817","DOI":"10.1002\/onco.13721","volume":"26","author":"X Yang","year":"2021","unstructured":"Yang X, Lalibert\u00e9 F, Germain G et al (2021) Real-world characteristics, treatment patterns, health care resource use, and costs of patients with diffuse large B cell lymphoma in the US. Oncologist 26(5):e817\u2013e826","journal-title":"Oncologist"},{"issue":"2","key":"4660_CR34","doi-asserted-by":"publisher","first-page":"196","DOI":"10.6004\/jnccn.2016.0023","volume":"14","author":"A Zelenetz","year":"2016","unstructured":"Zelenetz A, Gordon L, Wierda W et al (2016) Diffuse large B cell lymphoma version 1. J Natl Compr Canc 14(2):196\u2013231","journal-title":"J Natl Compr Canc"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04660-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04660-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04660-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T17:19:35Z","timestamp":1690478375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04660-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,5]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["4660"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04660-y","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,5]]},"assertion":[{"value":"8 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JM, SR and MP are employees of Miltenyi Biomedicine GmbH. BW is an employee of Team Gesundheit, a contract research company that received funding from Miltenyi Biomedicine to conduct the study in line with the study protocol. PB and J-MH are employed at the University Hospital Cologne. All authors have no other relevant affiliations or financial involvement with any other organization or entity with a financial interest in the subject matter or materials discussed in the manuscript apart from those disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All individual patient data are anonymized in the research database to comply with German data protection regulations. Institutional review board\/ethical approval and informed consent of the individuals were not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}